Abstract | BACKGROUND: METHOD: RESULTS: The addition of idazoxan to fluphenazine treatment resulted in significant reductions of global psychosis and total, positive and negative symptoms on the Brief Psychiatric Rating Scale, compared to neuroleptic treatment alone. Symptom improvement significantly correlated with idazoxan-induced changes in indices of noradrenergic function. In a subgroup of patients, idazoxan plus typical neuroleptic treatment compared favourably with clozapine treatment, when both were compared to typical neuroleptic treatment alone. CONCLUSIONS:
|
Authors | R E Litman, T P Su, W Z Potter, W W Hong, D Pickar |
Journal | The British journal of psychiatry : the journal of mental science
(Br J Psychiatry)
Vol. 168
Issue 5
Pg. 571-9
(May 1996)
ISSN: 0007-1250 [Print] England |
PMID | 8733795
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Adrenergic alpha-Antagonists
- Antipsychotic Agents
- Dioxanes
- Imidazoles
- Clozapine
- Fluphenazine
- Idazoxan
|
Topics |
- Adrenergic alpha-Antagonists
(administration & dosage)
- Adult
- Antipsychotic Agents
(administration & dosage, adverse effects)
- Clozapine
(administration & dosage, adverse effects)
- Dioxanes
(administration & dosage, adverse effects)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Fluphenazine
(administration & dosage, adverse effects)
- Humans
- Idazoxan
- Imidazoles
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Psychiatric Status Rating Scales
- Schizophrenia
(diagnosis, drug therapy)
- Schizophrenic Psychology
- Treatment Outcome
|